Angiotensin-converting enzyme inhibitors: new orally active 1,4-thiazepine-2,5-diones, 1,4-thiazine-2,5-diones, and 1,4-benzothiazepine-2,5-diones possessing antihypertensive activity

Authors:
  • JSJerry W. Skiles
    Jerry W. Skiles
  • JSJohn T. Suh
    John T. Suh
  • BWBruce E. Williams
    Bruce E. Williams
  • PMPaul R. Menard
    Paul R. Menard
  • JBJeffrey N. Barton
    Jeffrey N. Barton
  • BLBernard Loev
    Bernard Loev
  • HJHoward Jones
    Howard Jones
  • ENEdward S. Neiss
    Edward S. Neiss
  • ASAlfred Schwab
    Alfred Schwab
Publisher website
Google Scholar
Abstract
The preparation of a series of 1,4-thiazepine-2,5-diones,1,4-thiazine-2,5-diones, and 1,4-benzothiazepine-2,5-diones and their ability in inhibiting the activity of angiotensin-converting enzyme (ACE) in vitro and in vivo were examined. These compounds are assumed to act as prodrugs since they undergo rapid ring-opening reactions to give the corresponding biologically active free SH compounds when incubated with rat plasma or when treated with aqueous 0.1 N HCl or phosphate buffer (pH 7.4). The thiazepines 23-25 and 30 are potent inhibitors of ACE when administered po to rats and are comparable in potency to captopril (1). The most active thiazines in rats, po, were 42 and 45. Of the benzothiazepines studied, 22a was the most active in inhibiting ACE in the conscious normotensive rat, ID50 = 0.15 mg/kg, po. The acute antihypertensive effects of oral administration of a number of these compounds on mean arterial pressure and heart rate were studied in spontaneously hypertensive rats (SHR) maintained on a sodium-deficient diet.

This publication has 35 references indexed in Scilit: